|
307 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...7475767778798081828384...9899» |
- | Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P4 trial: Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers (clinicaltrials.gov) - Jan 9, 2013
P4, N=100, Recruiting, Sponsor: Massachusetts General Hospital
- | Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1 trial: Clinical Pharmacology Study of MP-424 (clinicaltrials.gov) - Jan 9, 2013
P1, N=26, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
- morphine sulphate / Generic mfg.
Biomarker, New P1 trial: Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease (clinicaltrials.gov) - Jan 9, 2013
P1, N=30, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- |||| ombitasvir (ABT-267) / AbbVie
Enrollment open, Combination therapy: A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study (clinicaltrials.gov) - Jan 9, 2013
P2, N=93, Enrolling by invitation, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Enrolling by invitation
- faldaprevir (BI201335) / Boehringer Ingelheim
Trial completion: Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules (clinicaltrials.gov) - Jan 9, 2013
P1, N=60, Completed, Sponsor: Boehringer Ingelheim Pharmaceuticals
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial termination: Polycystic Liver Disease in Kidney Transplant (clinicaltrials.gov) - Jan 8, 2013
P=N/A, N=2, Terminated, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Terminated; Terminated due to inadequate enrollment
- sirolimus / Generic mfg.
Enrollment change: Polycystic Liver Disease in Kidney Transplant (clinicaltrials.gov) - Jan 8, 2013
P=N/A, N=2, Terminated, Sponsor: Mayo Clinic
Recruiting --> Terminated; Terminated due to inadequate enrollment N=68 --> 2
- tacrolimus intravenous / Generic mfg.
Clinical: Randomized Controlled Trial of ImmuKnow in Liver Transplantation (clinicaltrials.gov) - Jan 7, 2013
P=N/A, N=206, Completed, Sponsor: University of Bologna
- codrituzumab (RG7686) / Roche
Enrollment change, Combination therapy, Metastases: Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) (clinicaltrials.gov) - Jan 7, 2013
P1, N=40, Active, not recruiting, Sponsor: Chugai Pharmaceutical
N=68 --> 2 N=31 --> 40
- ||| Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
Enrollment closed: A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 7, 2013
P2, N=96, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=31 --> 40 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- DC Bead (E7040) / Eisai, Boston Scientific
Trial completion, Metastases: Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas (clinicaltrials.gov) - Jan 7, 2013
P1, N=18, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| Trial initiation date: Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure (clinicaltrials.gov) - Jan 6, 2013
P3, N=200, Recruiting, Sponsor: Vital Therapies, Inc.
Recruiting --> Completed Initiation date: Oct 2012 --> Feb 2013
- New P2 trial: Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant (clinicaltrials.gov) - Jan 6, 2013
P2, N=18, Completed, Sponsor: Federal University of Minas Gerais
- AZD1480 / AstraZeneca
Trial termination, Metastases, Biopsy: A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. (clinicaltrials.gov) - Jan 6, 2013
P1, N=47, Terminated, Sponsor: AstraZeneca
Initiation date: Oct 2012 --> Feb 2013 Suspended --> Terminated; Compound development discontinued
- ||| entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change: Suboptimal Responders to Adefovir Switching to Entecavir (clinicaltrials.gov) - Jan 3, 2013
P4, N=228, Completed, Sponsor: Bristol-Myers Squibb
Suspended --> Terminated; Compound development discontinued N=169 --> 228
- | Inrebic (fedratinib) / BMS
New P1 trial: Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment (clinicaltrials.gov) - Jan 3, 2013
P1, N=17, Completed, Sponsor: Sanofi
- | Victoza (liraglutide) / Novo Nordisk
New P4 trial: MAGNA VICTORIA: Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients (clinicaltrials.gov) - Jan 2, 2013
P4, N=50, Recruiting, Sponsor: Leiden University Medical Center
- |||||||||| Pegberon (ypeginterferon alpha-2b) / Xiamen Amoytop Biotech
New P3 trial: Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B (clinicaltrials.gov) - Jan 1, 2013
P3, N=818, Recruiting, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
- | azithromycin / Generic mfg.
New P2 trial: Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jan 1, 2013
P2, N=100, Completed, Sponsor: Tehran University of Medical Sciences
- metadoxine / Generic mfg.
Enrollment open: A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease (clinicaltrials.gov) - Jan 1, 2013
P2, N=83, Recruiting, Sponsor: Brown University
N=169 --> 228 Not yet recruiting --> Recruiting
- Enrollment change: Effective Treatment of Hepatitis C in Substance Users (clinicaltrials.gov) - Dec 31, 2012
P=N/A, N=21, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting N=12 --> 21
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment change: CUPIC: French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=675, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=12 --> 21 N=900 --> 675
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, Victrelis (boceprevir) / Roche, Merck (MSD)
Enrollment closed: CUPIC: French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (clinicaltrials.gov) - Dec 25, 2012
P=N/A, N=675, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
N=900 --> 675 Recruiting --> Active, not recruiting
- Trial completion: Patient Specific Induced Pluripotency Stem Cells (PSiPS) (clinicaltrials.gov) - Dec 24, 2012
P=N/A, N=15, Completed, Sponsor: Royan Institute
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 23, 2012
P2b, N=249, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion: A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment (clinicaltrials.gov) - Dec 23, 2012
P1, N=24, Completed, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Active, not recruiting Recruiting --> Completed
- epirubicin / Generic mfg.
Trial completion: PRECISION-IT: Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE (clinicaltrials.gov) - Dec 20, 2012
P4, N=178, Completed, Sponsor: Rita Golfieri
Recruiting --> Completed Active, not recruiting --> Completed
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial termination: BMS-247550 in Treating Patients With Liver or Gallbladder Cancer (clinicaltrials.gov) - Dec 20, 2012
P2, N=50, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Metastases: Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Dec 20, 2012
P0, N=12, Recruiting, Sponsor: Case Comprehensive Cancer Center
Completed --> Terminated Not yet recruiting --> Recruiting
- ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Trial termination: Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia (clinicaltrials.gov) - Dec 19, 2012
P2, N=10, Terminated, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Completed --> Terminated; Schering-Plough discontinued supplying study drug.
- ||| Olysio (simeprevir) / J&J, Medivir
Trial initiation date, Combination therapy: A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (clinicaltrials.gov) - Dec 19, 2012
P2a, N=168, Completed, Sponsor: Janssen R&D Ireland
Completed --> Terminated; Schering-Plough discontinued supplying study drug. Initiation date: Oct 2011 --> Jan 2012
- |||||||||| peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
New P3 trial, Combination therapy: Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C (clinicaltrials.gov) - Dec 19, 2012
P3, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
- |||||||||| Adomet (S-adenosyl-L-methionine) / Abbott
New P3 trial, IO biomarker: Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group (clinicaltrials.gov) - Dec 19, 2012
P3, N=120, Recruiting, Sponsor: Abbott
- sorafenib / Generic mfg.
New P1/2 trial, Metastases: A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective (clinicaltrials.gov) - Dec 19, 2012
P1/2, N=48, Recruiting, Sponsor: Thomas Jefferson University
- |||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment open, Combination therapy: Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Na (clinicaltrials.gov) - Dec 19, 2012
P3, N=70, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Initiation date: Oct 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Doxorubicin and Bortezomib in Treating Patients With Liver Cancer (clinicaltrials.gov) - Dec 19, 2012
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Pegasys (pegylated interferon α -2a) / Roche
Enrollment change: Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C (clinicaltrials.gov) - Dec 18, 2012
P4, N=42, Completed, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed N=32 --> 42
- Pegasys (pegylated interferon α -2a) / Roche
Trial completion: Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C (clinicaltrials.gov) - Dec 18, 2012
P4, N=42, Completed, Sponsor: National Taiwan University Hospital
N=32 --> 42 Recruiting --> Completed
- Pegasys (pegylated interferon ? -2a) / Roche
Trial termination, Combination therapy: Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load (clinicaltrials.gov) - Dec 18, 2012
P4, N=59, Terminated, Sponsor: National Taiwan University Hospital
Recruiting --> Completed Recruiting --> Terminated; Novel HCV DAA approved by FDA
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change, Combination therapy: Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load (clinicaltrials.gov) - Dec 18, 2012
P4, N=59, Terminated, Sponsor: National Taiwan University Hospital
Recruiting --> Terminated; Novel HCV DAA approved by FDA N=116 --> 59
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change: Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR (clinicaltrials.gov) - Dec 18, 2012
P4, N=962, Recruiting, Sponsor: National Taiwan University Hospital
N=116 --> 59 N=700 --> 962
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial, Combination therapy: Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Na (clinicaltrials.gov) - Dec 18, 2012
P3, N=70, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P3 trial, Combination therapy: Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Na (clinicaltrials.gov) - Dec 18, 2012
P3, N=50, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- L-ornithine-L-aspartate / Generic mfg.
Trial completion: The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS (clinicaltrials.gov) - Dec 17, 2012
P2/3, N=40, Completed, Sponsor: Fourth Military Medical University
N=700 --> 962 Recruiting --> Completed
- colesevelam / Generic mfg.
Trial completion: COPE: Colesevelam Versus Placebo in Cholestatic Pruritus (clinicaltrials.gov) - Dec 16, 2012
P2/3, N=38, Completed, Sponsor: Foundation for Liver Research
Recruiting --> Completed Active, not recruiting --> Completed
- ||| insulin peglispro (LY2605541) / Eli Lilly
New P1 trial: A Single Dose Study of LY2605541 in Participants With Liver Impairment (clinicaltrials.gov) - Dec 16, 2012
P1, N=60, Completed, Sponsor: Eli Lilly and Company
- Enrollment change: ALFAE: Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis (clinicaltrials.gov) - Dec 13, 2012
P4, N=56, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Active, not recruiting --> Completed N=124 --> 56
- || New P3 trial: CIK Treatment for HCC Patient Underwent Radical Resection (clinicaltrials.gov) - Dec 13, 2012
P3, N=200, Recruiting, Sponsor: Sun Yat-sen University
- |||||| ViraferonPeg (peginterferon-α-2b) / Merck (MSD)
Enrollment open: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) (clinicaltrials.gov) - Dec 13, 2012
P3, N=1400, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=124 --> 56 Not yet recruiting --> Recruiting